Send to

Choose Destination
J Clin Gastroenterol. 2019 Feb;53(2):147-154. doi: 10.1097/MCG.0000000000001078.

Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C.

Author information

Department of Medicine, Division of Gastroenterology and Hepatology, NYU Langone Health, NYU School of Medicine.
Beijing Youan Hospital, Capital Medical University, Beijing, China.
Interfaith Medical Center.
University of the East Ramon Magsaysay Memorial Medical Center Inc., Quezon City, NCR, Philippines.
Division of Gastroenterology and Hepatology, University of California, Irvine, School of Medicine, Orange.
Pfleger Liver Institute, David Geffen School of Medicine at UCLA.
Division of Gastroenterology and Hepatology, Huntington Medical Research Institutes, Pasadena, CA.
Downtown Gastroenterology PC, New York.
Division of Hepatology, Sandra Atlas Bass Center for Liver Disease, Donald and Barbara Zucker School of Medicine at Hofstraa/Northwell Health, Manhasset.
Transplant Hepatology, University of Miami Miller School of Medicine, Miami, FL.
Division of Gastroenterology and Hepatology, Hahnemann University Hospital, Drexel College of Medicine, Philadelphia, PA.
Division of Gastroenterology and Hepatology, SUNY Downstate Medical Center.
Division of Gastroenterology and Hepatology, NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn.
Saint Johns University, Jamaica, NY.



Limited data exist with regard to treatment outcomes in Asian Americans with chronic hepatitis C (CHC). We evaluated sofosbuvir (SOF)-based regimens in a national cohort of Asian Americans.


Eligible Asian Americans patients with CHC who had posttreatment follow-up of 24 weeks for SOF -based therapies from December 2013 to June 2017 were enrolled from 11 sites across the United States. The primary endpoint was sustained virologic response (SVR) rates at posttreatment weeks 12 and 24. Secondary endpoints were to evaluate safety by tolerability and adverse events (AEs).


Among 231 patients screened, 186 were enrolled. At baseline, 31% (57/186) patients were cirrhotic, 34% (63/186) were treatment experienced. Most of the subjects (42%, 79/186) received ledispavir/SOF therapy. The overall SVR12 was 95%, ranging from 86% in genotype (GT) 1b on SOF+ribavirin to 100% in GT 1b patients on ledipasvir/SOF at subgroup analyses. SVR12 was significantly lower in cirrhotic than in noncirrhotic patients [88% (50/57) vs. 98% (126/129), P<0.01]. Stratified by GT, SVR12 were: 96% (43/45) in GT 1a; 93% (67/72) in GT 1b; 100% (23/23) in GT 2; 90% (19/21) in GT 3; 100% (1/1) in GT 4; 83% (5/6) in GT 5; and 100% (16/16) in GT 6. Cirrhotic patients with treatment failure were primarily GT 1, (GT 1a, n=2; GT 1b, n=4) with 1 GT 5 (n=1). Patients tolerated the treatment without serious AEs. Late relapse occurred in 1 patient after achieving SVR12.


In Asian Americans with CHC, SOF-based regimens were well tolerated without serious AEs and could achieve high SVR12 regardless of hepatitis C viral infection GT.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center